NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today’s Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate):
“We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office’s…
